Biotech
VANCOUVER, BRITISH COLUMBIA: VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/20/11 -- (TSX: NPC) announced today that it has successfully achieved the enrollment objective of 300 patients in the phase 2/3 pivotal clinical tri ...
ROCKVILLE, MD: CORE Designed to Match Talented Jobseekers With Maryland Tech Companies ...
BOTHELL, WA: BOTHELL, WA -- (Marketwire) -- 10/19/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that it will present at The 10 ...
MOUNTAINSIDE, NJ: MOUNTAINSIDE, NJ -- (Marketwire) -- 10/19/11 -- PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, a ...
SOUTH SAN FRANCISCO, CA: SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 10/19/11 -- Theravance, Inc. (NASDAQ: THRX) today announced that data from a GlaxoSmithKline (GSK) Phase 2b study of GSK573719, a long-acting muscarinic an ...
LONDON, ONTARIO: LONDON, ONTARIO -- (Marketwire) -- 10/19/11 -- Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) announced today that 71,449 stock options were approved for grant under the Company's ...
VANCOUVER, BRITISH COLUMBIA: VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/19/11 -- Fox Resources Ltd. (TSX VENTURE: FAX) announces that it signed a Share Purchase Agreement to acquire all of the issued and outstanding memb ...
MONTREAL, CANADA: MONTREAL, CANADA -- (Marketwire) -- 10/19/11 -- Theratechnologies Inc. (TSX: TH)(NASDAQ: THER) today announced that an affiliate of Sanofi, its commercial partner, has submitted a marketing authoriz ...
BUFFALO, NY: Roswell Park Cancer Institute Approves First Trial Protocol ...
BOTHELL, WA: A microRNA (miRNA) Antagonist Substituted With Marina Biotech's Proprietary Conformationally Restricted Nucleotides (CRN) Produced Dose-Dependent, In Vivo De-Repression of Multiple Downstream Tar ...
SAN DIEGO, CA: SAN DIEGO, CA -- (Marketwire) -- 10/19/11 -- Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that additional data from the ongoing extension portion of a Phase 2b study (Study 203) of lesinur ...
OTTAWA, ONTARIO: OTTAWA, ONTARIO -- (Marketwire) -- 10/19/11 -- PharmaGap Inc. (TSX VENTURE: GAP)(OTCBB: PHRGF)("PharmaGap" or "the Company") is pleased to report that quality audits for cGMP (cu ...
TORONTO, ONTARIO: TORONTO, ONTARIO -- (Marketwire) -- 10/18/11 -- RXT 110 INC. (CNSX: RXT) (the "Company") announced today that it has commenced legal proceedings against Donald Mark Meade, Rx110 Inc., Rx10 ...
AURORA, ON: AURORA, ON -- (Marketwire) -- 10/18/11 -- Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP), today announced that the directors have received a shareholder requisition to call a mee ...
SEATTLE, WA: SEATTLE, WA -- (Marketwire) -- 10/18/11 -- ALLOZYNE, Inc. announced today positive initial results from its multiple ascending dose (MAD) phase IB trial for its lead product candidate, AZ01, a clin ...
SOUTH SAN FRANCISCO, CA: Company Aligns Resources to Focus on the Late-Stage Development of CK-2017357 in ALS and Omecamtiv Mecarbil in Heart Failure ...
VANCOUVER, BRITISH COLUMBIA: VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/18/11 -- (the "Company" or "RepliCel") (OTCBB: REPCF) announces that has commenced . Updated weekly, this factual information w ...
PALO ALTO, CA: Funding to Support Phase 2b/3 Clinical Development Program of Luliconazole for the Treatment of Onychomycosis ...
BOTHELL, WA: BOTHELL, WA -- (Marketwire) -- 10/18/11 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced data presentations for eteplirsen (the non-proprietary name assi ...
MONTREAL, CANADA: MONTREAL, CANADA -- (Marketwire) -- 10/18/11 -- MethylGene Inc. (TSX: MYG) today announced that it has received approval for its initial Investigational New Drug (IND) application from the US Food a ...
